The study, published in Cell Death Discovery by Lijun Zhang, Yan Li, and colleagues at Shandong Second Medical University, focuses on metallothionein 3, a small protein with a remarkable capacity to bind metal ions. The researchers set out to determine whether MT3 influences the development of RIRI by regulating a copper transport pathway known as the Atox1–ATP7a axis, thereby modulating cuproptosis, a form of regulated cell death that was only identified in recent years and had not previously been fully characterized in the context of retinal injury. The work combines transcriptomic sequencing, bioinformatic analysis, a rat model of retinal ischemia–reperfusion, cell culture experiments, recombinant protein rescue studies, and a battery of complementary molecular assays.

Cuproptosis entered the scientific vocabulary only recently, and its discovery reshaped how researchers think about metal-mediated cell death. Unlike apoptosis, necroptosis, or ferroptosis, cuproptosis depends directly on copper ions. In the canonical model, excess copper binds to lipid-acylated components of the mitochondrial tricarboxylic acid cycle, causing those proteins to aggregate. The result is a collapse of mitochondrial function, proteotoxic stress, and ultimately cell death. Because copper is an essential trace element that participates in respiration, antioxidant defense, and enzyme catalysis, cells must maintain it within narrow limits. Too little copper cripples metabolism; too much triggers the lethal aggregation that defines cuproptosis. Understanding how cells manage this delicate balance during disease has become a rapidly growing field.

The copper transport machinery at the center of the new study is a two-part system. Atox1, short for antioxidant 1 copper chaperone, is a small protein that ferries copper ions through the cell’s interior, delivering them to ATP7a, a copper-transporting adenosine triphosphatase embedded in cellular membranes. ATP7a then pumps copper out of the cell or routes it to copper-dependent enzymes. Together, this axis acts as a controlled export pathway, a molecular pump-and-chaperone system that keeps intracellular copper from accumulating to dangerous levels. When the axis falters, copper ions that should be expelled remain inside the cell, where they can participate in the protein aggregation and mitochondrial damage characteristic of cuproptosis.

Using their rat model of retinal ischemia–reperfusion injury, the researchers gathered evidence that cuproptosis occurs in retinal ganglion cells following RIRI. Retinal ganglion cells are the neurons whose long axons form the optic nerve, carrying visual signals from the eye to the brain. Their loss is irreversible, which is why ganglion cell death is the decisive event in glaucoma and many other blinding diseases. Demonstrating that this specific, copper-dependent death program operates in ganglion cells after ischemia–reperfusion adds an important new dimension to the cell death landscape of the retina, which researchers had previously mapped largely in terms of apoptosis and other better-studied pathways.

But the most striking finding concerned a different cell type. The researchers found that MT3 expression was markedly downregulated in retinal Müller cells, the glial cells that span the entire thickness of the retina and provide structural, metabolic, and homeostatic support to neurons. Müller cells are the workhorses of retinal maintenance: they regulate the chemical environment of the retina, buffer neurotransmitters, and help manage water and ion balance. The team found that this downregulation of MT3 was associated with impaired function of the Atox1–ATP7a copper transport axis, decreased copper ion efflux, and enhanced cuproptosis-related injury in Müller cells, ultimately exacerbating retinal damage. In other words, when MT3 levels fell, the copper export machinery weakened, copper accumulated, and the glial cells that support the retina suffered copper-driven injury.

To test whether this relationship was causal rather than merely correlational, the researchers turned to rescue experiments using recombinant MT3 protein. By supplying the protein experimentally, they could ask whether restoring MT3 function would protect cells from the cascade of copper accumulation and cuproptosis-related damage. Combined with their R28 retinal cell culture system and complementary molecular assays, these experiments allowed the team to build a mechanistic chain linking MT3, the Atox1–ATP7a axis, copper efflux, and cell survival. The study thereby explains, in mechanistic depth, how MT3 regulates cuproptosis through the Atox1–ATP7a axis in retinal ischemia–reperfusion injury.

The technical approach behind these conclusions reflects the modern toolkit of cell death research. Transcriptomic sequencing allowed the team to survey gene expression across the retina after injury, and bioinformatic analysis helped identify MT3 as a candidate regulator within the copper-handling network. The rat RIRI model, in which blood flow to the retina is temporarily interrupted and then restored, reproduces the ischemia–reperfusion conditions relevant to human ocular disease. R28 cells, a retinal precursor-derived cell line, provided a controlled in vitro environment for molecular manipulation, while recombinant MT3 protein enabled rescue experiments that tested the pathway’s function directly. Together, these complementary approaches strengthen the evidence that the MT3–Atox1–ATP7a–cuproptosis axis is a genuine regulatory circuit rather than an incidental association.

The clinical implications are significant. Because effective targeted therapeutic approaches for RIRI remain limited, the identification of MT3 as a regulator of copper-dependent injury suggests a promising novel therapeutic target. If MT3 levels could be preserved or restored in the retina after ischemic events, the copper export machinery might continue functioning, limiting cuproptosis-related damage to Müller cells and, by extension, reducing the secondary injury that spreads to vulnerable retinal ganglion cells. Such a strategy would represent a departure from current approaches that focus on lowering intraocular pressure or broadly suppressing inflammation, instead intervening at the level of a specific regulated cell death program and its metal-handling machinery.

The study also adds to a broader shift in biomedical science, in which cell death is understood not as a single failure mode but as a family of precisely regulated programs, each with its own triggers, molecular machinery, and therapeutic vulnerabilities. Copper, long appreciated mainly as an essential nutrient, has now been implicated as an active executioner in the retina under ischemic stress, with a specific chaperone-and-pump system serving as the gatekeeper. As researchers continue to map the roles of cuproptosis across tissues and diseases, the retina joins the growing list of organs in which metal ion homeostasis may prove to be the difference between recovery and irreversible damage. For the millions of people at risk of vision loss from retinal ischemia, that distinction could one day translate into new treatments built on a small copper-binding protein and the transport axis it controls.

Subject of Research: Regulation of cuproptosis by metallothionein 3 via the Atox1–ATP7a copper transport axis in retinal ischemia–reperfusion injury

Article Title: Metallothionein 3 regulates cuproptosis in rat retinal ischemia-reperfusion injury via the Atox1–ATP7a axis

Article References: Zhang, L., Li, Y., Liu, Z., Yu, F., Luo, J., Ci, R., Wang, X., & Zhao, Y. (2026). Metallothionein 3 regulates cuproptosis in rat retinal ischemia-reperfusion injury via the Atox1–ATP7a axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03386-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03386-3

Keywords: cuproptosis, metallothionein 3, retinal ischemia-reperfusion injury, Atox1, ATP7a, copper transport, retinal ganglion cells, Müller cells, cell death, retina, neuroprotection, glaucoma